- Home
- BTTC vs MBAI Comparison
BTTC vs MBAI Comparison
Compare BTTC & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTTC | MBAI |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | Malaysia | Israel |
| Employees | N/A | 85 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTTC | MBAI |
|---|---|---|
| Price | $0.93 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 160.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $1.29 |
| 52 Week High | $11.22 | $3.92 |
Technical Indicators
Market Signals| Indicator | BTTC | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 36.62 |
| Support Level | N/A | $1.30 |
| Resistance Level | $1.41 | $1.83 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 0.06 | 0.00 |
Price Performance
Historical ComparisonAbout BTTC Black Titan Corporation Ordinary Shares
Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.
About MBAI Check-Cap Ltd. Ordinary Share
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.